Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AVTR 
Avantor Inc (AVTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: AVTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
21 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $13.64
1 Year Target Price $13.64
| 6 | Strong Buy |
| 4 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -29.76% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.00B USD | Price to earnings Ratio - | 1Y Target Price 13.64 |
Price to earnings Ratio - | 1Y Target Price 13.64 | ||
Volume (30-day avg) 21 | Beta 0.93 | 52 Weeks Range 10.82 - 23.32 | Updated Date 11/30/2025 |
52 Weeks Range 10.82 - 23.32 | Updated Date 11/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -1.25% | Operating Margin (TTM) 8.48% |
Management Effectiveness
Return on Assets (TTM) 3.43% | Return on Equity (TTM) -1.48% |
Valuation
Trailing PE - | Forward PE 12.3 | Enterprise Value 11603688296 | Price to Sales(TTM) 1.22 |
Enterprise Value 11603688296 | Price to Sales(TTM) 1.22 | ||
Enterprise Value to Revenue 1.76 | Enterprise Value to EBITDA 18 | Shares Outstanding 681814859 | Shares Floating 663835401 |
Shares Outstanding 681814859 | Shares Floating 663835401 | ||
Percent Insiders 1.39 | Percent Institutions 102.25 |
Upturn AI SWOT
Avantor Inc
Company Overview
History and Background
Avantor, Inc. (formerly known as VWR Corporation) was founded in 1904. It started as a chemical supply house and has evolved into a global provider of products and services to the life sciences and advanced technologies industries through organic growth and multiple acquisitions.
Core Business Areas
- Materials and Consumables: Offers a broad portfolio of high-purity materials, chemicals, lab supplies, and consumables used in research, development, and production.
- Equipment and Instrumentation: Provides laboratory and process equipment, instruments, and related services.
- Services and Specialty Solutions: Offers a range of value-added services, including lab and production support, single-use solutions, and bioprocessing solutions.
Leadership and Structure
Avantor is led by a CEO and a senior management team, with a board of directors providing oversight. The organizational structure is divided into business segments and functional areas.
Top Products and Market Share
Key Offerings
- High-Purity Chemicals: Avantor's high-purity chemicals are critical in pharmaceutical manufacturing and research. Market share information is proprietary, but the market is highly competitive. Competitors include Merck KGaA (MRK.DE), Thermo Fisher Scientific (TMO), and Danaher (DHR).
- Single-Use Solutions: Single-use solutions are used in biopharmaceutical manufacturing to reduce contamination risks and improve efficiency. Market share information is proprietary. Competitors include Sartorius (SRT.DE) and Cytiva (part of Danaher).
- Laboratory Equipment: Includes a variety of equipment used in labs, such as incubators, centrifuges, and bioreactors. Market share is fragmented and dependent on specific equipment categories. Competitors include Thermo Fisher Scientific (TMO) and Agilent Technologies (A).
Market Dynamics
Industry Overview
The life sciences and advanced technologies industries are characterized by ongoing innovation, increasing regulatory requirements, and growing demand for specialized products and services. The industry is highly competitive and technologically driven.
Positioning
Avantor is positioned as a leading provider of solutions for the life sciences and advanced technologies industries. It offers a broad portfolio and aims to be a strategic partner for its customers.
Total Addressable Market (TAM)
The estimated total addressable market for life sciences tools and services is in the hundreds of billions of dollars. Avantor is well-positioned to capture a significant share of this market through its diverse offerings and global presence.
Upturn SWOT Analysis
Strengths
- Broad Product Portfolio
- Global Presence
- Strong Customer Relationships
- Extensive Distribution Network
- Reputation for Quality
Weaknesses
- High Debt Levels (relative to some competitors)
- Integration Risks from Acquisitions
- Exposure to Economic Cycles
- Customer concentration
Opportunities
- Growing Demand for Biopharmaceuticals
- Increasing R&D Spending
- Expansion into Emerging Markets
- Technological Advancements
- New regulatory developments in precision medicine
Threats
- Increased Competition
- Pricing Pressure
- Regulatory Changes
- Supply Chain Disruptions
- Economic Downturns
Competitors and Market Share
Key Competitors
- TMO
- DHR
- MRK.DE
Competitive Landscape
Avantor faces competition from large, diversified companies and smaller, specialized players. Avantor's broad portfolio and global reach are advantages, but it must continue to innovate and differentiate its offerings.
Major Acquisitions
Masterflex Bioprocessing
- Year: 2021
- Acquisition Price (USD millions): 2300
- Strategic Rationale: Expanded Avantor's single-use bioprocessing capabilities and product offerings.
Growth Trajectory and Initiatives
Historical Growth: Avantor has experienced substantial growth through organic initiatives and strategic acquisitions.
Future Projections: Future growth is projected to be driven by increasing demand in the life sciences and advanced technologies industries, as well as continued expansion through acquisitions and new product development.
Recent Initiatives: Recent initiatives include expanding its bioprocessing solutions and investing in digital capabilities.
Summary
Avantor demonstrates strengths in its broad portfolio and global reach, positioning it well within the life sciences industry. However, its high debt levels and integration risks are areas for consideration. The company can leverage the rising demand for biopharmaceuticals and expand into emerging markets. Threats include intense competition, regulatory shifts and potential economic downturns.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Investor Presentations
- Press Releases
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough individual research and consultation with a qualified financial advisor. Market share data is based on available estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avantor Inc
Exchange NYSE | Headquaters Radnor, PA, United States | ||
IPO Launch date 2019-05-17 | President & CEO Mr. Emmanuel Ligner | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 13500 | Website https://www.avantorsciences.com |
Full time employees 13500 | Website https://www.avantorsciences.com | ||
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, peristaltic pumps, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, compound management, cleanroom control, monitoring, maintenance, and sanitization services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.